Congenital Transmission of Lineages I and II of Trypanosoma Cruzi
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/7/2015 |
| Start Date: | April 2011 |
| End Date: | February 2015 |
| Contact: | Pierre Buekens, MD, PhD |
| Email: | pbuekens@tulane.edu |
| Phone: | 504-988-5397 |
T. cruzi has been divided into two main lineages: T. cruzi I (TcI) and T. cruzi II (TcII,
including all non-TcI). TcI is predominant in Mexico and Central America, while TcII
(non-TcI) is predominant in most of South America, including Argentina. In recent studies
from Argentina, the risk of congenital transmission has been estimated to vary between 2.6
percent and 7.9 percent. By contrast, we know very little about the congenital transmission
of TcI. It has been suggested that congenital transmission of T. cruzi is strain related,
and there is an urgent need to know if TcI transmits differently than TcII (non-TcI). Our
primary hypothesis is that congenital transmission rates are different for TcI versus TcII.
Our secondary hypothesis is that the characteristics of T. cruzi infected mothers (e.g.,
age, parity, transmission in previous pregnancies) and their exposure to vectors are
different in regions where TcI is predominant versus regions where TcII (non-TcI) is
predominant. To test these hypotheses, we propose to conduct a prospective study to enroll
at delivery 13,000 women in Mexico, 7,500 women in Honduras, and 10,000 women in Argentina.
We will measure transmitted maternal T. cruzi antibodies in cord blood, and, if the results
are positive, we will identify infants who are congenitally infected by performing
parasitological examinations on cord blood and at 4-8 weeks, and serological follow-up at 10
months. We will also perform standard PCR, real-time quantitative PCR, and T. cruzi
genotyping on maternal blood, standard PCR and T. cruzi genotyping on the cord blood of
congenitally infected newborns, and serological examinations on siblings. We will estimate
the exposure to vectors in the household. In addition, we will measure prenatal outcomes
among infected and uninfected infants with seropositive mothers, and the birth weight of
their siblings. The specific aims of this study are: 1) To determine the rate of congenital
transmission of TcI compared to TcII (non-TcI); 2) To compare the T. cruzi infected mothers'
characteristics and exposure to vectors in regions where TcI is predominant and regions
where TcII (non-TcI) is predominant; and 3) To describe the birth outcomes of infected and
uninfected infants born to TcI and TcII seropositive women.
including all non-TcI). TcI is predominant in Mexico and Central America, while TcII
(non-TcI) is predominant in most of South America, including Argentina. In recent studies
from Argentina, the risk of congenital transmission has been estimated to vary between 2.6
percent and 7.9 percent. By contrast, we know very little about the congenital transmission
of TcI. It has been suggested that congenital transmission of T. cruzi is strain related,
and there is an urgent need to know if TcI transmits differently than TcII (non-TcI). Our
primary hypothesis is that congenital transmission rates are different for TcI versus TcII.
Our secondary hypothesis is that the characteristics of T. cruzi infected mothers (e.g.,
age, parity, transmission in previous pregnancies) and their exposure to vectors are
different in regions where TcI is predominant versus regions where TcII (non-TcI) is
predominant. To test these hypotheses, we propose to conduct a prospective study to enroll
at delivery 13,000 women in Mexico, 7,500 women in Honduras, and 10,000 women in Argentina.
We will measure transmitted maternal T. cruzi antibodies in cord blood, and, if the results
are positive, we will identify infants who are congenitally infected by performing
parasitological examinations on cord blood and at 4-8 weeks, and serological follow-up at 10
months. We will also perform standard PCR, real-time quantitative PCR, and T. cruzi
genotyping on maternal blood, standard PCR and T. cruzi genotyping on the cord blood of
congenitally infected newborns, and serological examinations on siblings. We will estimate
the exposure to vectors in the household. In addition, we will measure prenatal outcomes
among infected and uninfected infants with seropositive mothers, and the birth weight of
their siblings. The specific aims of this study are: 1) To determine the rate of congenital
transmission of TcI compared to TcII (non-TcI); 2) To compare the T. cruzi infected mothers'
characteristics and exposure to vectors in regions where TcI is predominant and regions
where TcII (non-TcI) is predominant; and 3) To describe the birth outcomes of infected and
uninfected infants born to TcI and TcII seropositive women.
Inclusion Criteria:
- Women 18 years old or more, informed consent, live birth.
Exclusion Criteria:
- Women residing outside of the follow-up area.
We found this trial at
1
site
Click here to add this to my saved trials
